TY - JOUR
T1 - A plasma miRNA-based classifier for small cell lung cancer diagnosis
AU - Saviana, Michela
AU - Romano, Giulia
AU - McElroy, Joseph
AU - Nigita, Giovanni
AU - Distefano, Rosario
AU - Toft, Robin
AU - Calore, Federica
AU - Le, Patricia
AU - Morales, Daniel Del Valle
AU - Atmajoana, Sarah
AU - Deppen, Stephen
AU - Wang, Kai
AU - Lee, L. James
AU - Acunzo, Mario
AU - Nana-Sinkam, Patrick
N1 - Publisher Copyright:
Copyright © 2023 Saviana, Romano, McElroy, Nigita, Distefano, Toft, Calore, Le, Morales, Atmajoana, Deppen, Wang, Lee, Acunzo and Nana-Sinkam.
PY - 2023
Y1 - 2023
N2 - Introduction: Small cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveillance remain significant challenges. The aberrant expression of circulating microRNAs (miRNAs/miRs) is reported in many tumors and can provide insights into the pathogenesis of tumor development and progression. Here, we conducted a comprehensive assessment of circulating miRNAs in SCLC with a goal of developing a miRNA-based classifier to assist in SCLC diagnoses. Methods: We profiled deregulated circulating cell-free miRNAs in the plasma of SCLC patients. We tested selected miRNAs on a training cohort and created a classifier by integrating miRNA expression and patients’ clinical data. Finally, we applied the classifier on a validation dataset. Results: We determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. Moreover, we found that a model comprising miR-375-3p, miR-320b, and miR-144-3p can be integrated with race and age to distinguish metastatic SCLC from a control group. Discussion: This study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.
AB - Introduction: Small cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveillance remain significant challenges. The aberrant expression of circulating microRNAs (miRNAs/miRs) is reported in many tumors and can provide insights into the pathogenesis of tumor development and progression. Here, we conducted a comprehensive assessment of circulating miRNAs in SCLC with a goal of developing a miRNA-based classifier to assist in SCLC diagnoses. Methods: We profiled deregulated circulating cell-free miRNAs in the plasma of SCLC patients. We tested selected miRNAs on a training cohort and created a classifier by integrating miRNA expression and patients’ clinical data. Finally, we applied the classifier on a validation dataset. Results: We determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. Moreover, we found that a model comprising miR-375-3p, miR-320b, and miR-144-3p can be integrated with race and age to distinguish metastatic SCLC from a control group. Discussion: This study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.
KW - biomarkers
KW - classifier
KW - microRNAs
KW - oncology
KW - small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85174632310&partnerID=8YFLogxK
U2 - 10.3389/fonc.2023.1255527
DO - 10.3389/fonc.2023.1255527
M3 - Article
AN - SCOPUS:85174632310
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1255527
ER -